BDTX (Black Diamond Therapeutics) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Black Diamond Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Black Diamond Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $-15.06 Mil. Black Diamond Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Black Diamond Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Black Diamond Therapeutics's current FCF Yield % is -78.54%.

The historical rank and industry rank for Black Diamond Therapeutics's FCF Margin % or its related term are showing as below:

BDTX's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -128.43
* Ranked among companies with meaningful FCF Margin % only.

Black Diamond Therapeutics FCF Margin % Historical Data

The historical data trend for Black Diamond Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Black Diamond Therapeutics FCF Margin % Chart

Black Diamond Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

Black Diamond Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Black Diamond Therapeutics's FCF Margin %

For the Biotechnology subindustry, Black Diamond Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Black Diamond Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Black Diamond Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Black Diamond Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Black Diamond Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-62.303	/	0
	=	%

Black Diamond Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-15.055	/	0
	=	%

Black Diamond Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Black Diamond Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Black Diamond Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Black Diamond Therapeutics Inc (NAS:BDTX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Main Street, 14th Floor, Cambridge, MA, USA, 02142

Website

https://www.blackdiamondtherapeutics.com

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Executives

Biotech Growth N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Ra Capital Nexus Fund, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali Behbahani	director, 10 percent owner	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Peter Kolchinsky	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David M. Epstein	director, officer: See Remarks	OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Sergey Yurasov	officer: CHIEF MEDICAL OFFICER	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E., SUITE 310, SEATTLE WA 98102
Elizabeth Buck	officer: CHIEF SCIENTIFIC OFFICER	C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Erika Jones	officer: SEE REMARKS	C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Fang Ni	officer: SEE REMARKS	C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Biotech Ag Bb	10 percent owner	SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Wendy L Dixon	director
Mark A. Velleca	director	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709